Management of Elevated Triglycerides with Low HDL

Patient Assessment

The patient has low HDL (28 mg/dL) 1
The patient has elevated triglycerides (228 mg/dL) 2
The patient is on atorvastatin 80 mg, which is a high-intensity statin therapy 3

Despite maximum statin therapy, triglycerides remain elevated (>150 mg/dL) with low HDL (<40 mg/dL), representing residual cardiovascular risk 4
This pattern of dyslipidemia (high triglycerides, low HDL) is common in patients with metabolic syndrome or diabetes and requires targeted intervention 1, 5

Adding fenofibrate to address the persistent triglyceride elevation is recommended 6, 7
Fenofibrate is preferred over gemfibrozil when combined with a statin due to lower risk of myopathy 7, 1
Fenofibrate has demonstrated triglyceride reductions of 35-54% in clinical trials 6
Omega-3 fatty acids (fish oils) may be considered as they can reduce triglycerides by variable amounts 2, 6
Icosapent ethyl (purified EPA) can be considered for patients with established cardiovascular disease or risk factors with triglycerides 135-499 mg/dL 5

The combination of statins and fibrates increases risk of muscle toxicity; monitor for muscle pain and check CK levels periodically 7, 1
Monitor liver function tests regularly when using combination therapy 7
Reassess lipid profile 4-12 weeks after initiating combination therapy 4

Avoid niacin: Statin plus niacin combination therapy has not been shown to provide additional cardiovascular benefit and may increase stroke risk 1, 5
Avoid excessive alcohol consumption which can worsen hypertriglyceridemia 6
Don't overlook lifestyle modifications: weight loss, exercise, reduced simple carbohydrate intake, and limited alcohol consumption remain important 6, 4
Don't add medications without addressing underlying causes such as poorly controlled diabetes, which can significantly contribute to hypertriglyceridemia 4

The American Diabetes Association recommends that icosapent ethyl 2-4g daily can be considered as an alternative or additional therapy if patients have established cardiovascular disease or diabetes with ≥2 additional risk factors and triglycerides remain 135-499 mg/dL after 3 months of optimized therapy, with a demonstrated 25% reduction in major adverse cardiovascular events in the REDUCE-IT trial for patients on statin therapy with controlled LDL but elevated triglycerides 8